Fig. 1: SARS-CoV-2 variants causing the severe-critical COVID-19 endpoints. | Nature Communications

Fig. 1: SARS-CoV-2 variants causing the severe-critical COVID-19 endpoints.

From: Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial

Fig. 1

Variants are shown by calendar date of severe-critical COVID-19 occurrence and are broken out by geographic region (a, Latin America; b, USA; c, South Africa) and treatment assignment. Endpoint counts do not require having D1 and D29 antibody marker data (see the flowchart provided as Supplementary Fig. 2). As in Sadoff et al.5, “Reference” refers to the index strain (GenBank accession number: MN908947.3) harboring the D614G point mutation.

Back to article page